54 Participants Needed

Liposomal Bupivacaine for Healthy Volunteers

CB
AB
LR
Overseen ByLisa Ramsay

Trial Summary

Will I have to stop taking my current medications?

The trial requires that you stop taking opioid medications and NSAIDs (non-steroidal anti-inflammatory drugs) at least 3 days before the study drug is given. If you are on neuromodulating agents for pain control, you cannot participate, but if you take them for other reasons, you must be on a stable dose for at least 1 month before the study.

What data supports the effectiveness of the drug Liposomal Bupivacaine 13.3?

Liposomal Bupivacaine is shown to provide pain relief for up to 72 hours after surgery, as it is designed to release the medication slowly over time. It has been used effectively for pain management in surgical settings, such as lumbar fusions, and is approved by the FDA for this purpose.12345

Is liposomal bupivacaine safe for humans?

Liposomal bupivacaine has been shown to be safe in various studies, including those involving healthy volunteers and surgical patients. It has been approved by the FDA for managing postsurgical pain and has demonstrated safety across different procedures.24678

How is liposomal bupivacaine different from other drugs?

Liposomal bupivacaine is unique because it is a special formulation that releases the drug slowly over 72 hours, providing longer-lasting pain relief compared to regular bupivacaine. This makes it particularly useful for managing pain after surgery.12459

What is the purpose of this trial?

This trial tests a new slow-release pain-relief drug called Liposomal Bupivacaine 13.3 in healthy adults to ensure it is safe and well-tolerated. Liposomal bupivacaine is designed to provide extended postsurgical pain relief and reduce opioid consumption.

Research Team

SZ

Sergey Zaets

Principal Investigator

Pacira Pharmaceuticals, Inc

Eligibility Criteria

Healthy adults aged 18-50, with no history of severe headaches, back conditions, or chronic pain. Participants must not have allergies to study medications like bupivacaine and should not be on certain medications like corticosteroids before the trial. Women must not be pregnant or nursing.

Inclusion Criteria

American Society of Anesthesiologists physical status 1
Able to provide informed consent, adhere to the study schedule, and complete all study assessments

Exclusion Criteria

I have a bleeding risk or a blood clotting disorder with low platelets.
I am not allergic or intolerant to the study's medications.
Currently pregnant, nursing, or planning to become pregnant during the study
See 15 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single intrathecal injection of Liposomal Bupivacaine 13.3, bupivacaine, or placebo, followed by a 5-day stay in the Early Phase Research Unit

1 week
5 days in Early Phase Research Unit

Follow-up

Participants are monitored for safety and effectiveness after treatment, including a follow-up visit on Day 9 and a phone call on Day 30

4 weeks
1 visit (in-person), 1 phone call

Treatment Details

Interventions

  • Liposomal Bupivacaine 13.3
Trial Overview The safety and effects of Liposomal Bupivacaine 13.3 are being tested when given as a single spinal injection to healthy volunteers. The trial will also measure how the drug moves through and affects the body.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Liposomal Bupivacaine 13.3Experimental Treatment1 Intervention
Cohort 1 subjects will be dosed 2 mL (26.6 mg) of Liposomal Bupivacaine 13.3. Cohort 2 subjects randomized to the Liposomal Bupivacaine 13.3 arm will be dosed 3 mL (39.9 mg) of Liposomal Bupivacaine 13.3. Cohort 3 subjects randomized to the Liposomal Bupivacaine 13.3 arm will be dosed 4 mL (53.2 mg) of Liposomal Bupivacaine 13.3.
Group II: Bupivacaine ITActive Control1 Intervention
Cohort 1 subjects randomized to the bupivacaine arm will be dosed 2 mL (7.5 mg/ 1 mL) of 0.75% bupivacaine. Cohort 2 subjects randomized to the bupivacaine arm will be dosed 2 mL (7.5 mg/ 1 mL) of 0.75% bupivacaine mixed with 1 mL of preservative free normal saline to create a total volume of solution administered of 3 mL. Cohort 3 subjects randomized to the bupivacaine arm will be dosed 2 mL (7.5 mg / 1 mL) of 0.75% bupivacaine mixed with 2 mL of preservative free normal saline to create a total volume of solution administered of 4 mL.
Group III: PlaceboPlacebo Group1 Intervention
Cohort 1 subjects randomized to the placebo arm will be dosed 2 mL of preservative free normal saline. Cohort 2 subjects randomized to the placebo arm will be dosed 3 mL of preservative free normal saline. Cohort 3 subjects randomized to the placebo arm will be dosed 4 mL of preservative free normal saline.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Pacira Pharmaceuticals, Inc

Lead Sponsor

Trials
142
Recruited
14,300+
Headquarters
Tampa, USA
Known For
Non-opioid Pain Management
Top Products
Exparel, Zilretta, iovera
Dr. Jonathan Slonin profile image

Dr. Jonathan Slonin

Pacira Pharmaceuticals, Inc

Chief Medical Officer since 2020

BSc in Biomedical Engineering and MD from University of Miami, MBA from George Washington University

Frank D. Lee

Pacira Pharmaceuticals, Inc

Chief Executive Officer since 2024

BSc in Chemical Engineering from Vanderbilt University, MBA from Wharton Graduate School of Business

Findings from Research

Liposomal bupivacaine, administered in single or repeated doses, showed a maximum plasma concentration (C max) that remained well below the toxicity thresholds for neurotoxicity and cardiac toxicity, indicating a strong safety profile.
The study demonstrated that both single and repeated doses of liposomal bupivacaine were well-tolerated in healthy volunteers, with no significant adverse effects on neurologic or cardiac function.
Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers.Rice, D., Heil, JW., Biernat, L.[2018]
In a study involving 823 patients across various surgical settings, liposome bupivacaine demonstrated a lower incidence of adverse events (62%) compared to bupivacaine HCl (75%) and placebo (43%), indicating better tolerability.
Serious adverse events were less common in the liposome bupivacaine group (2.7%) compared to bupivacaine HCl (5.4%), suggesting that liposome bupivacaine may be a safer option for local analgesia.
The safety of liposome bupivacaine, a novel local analgesic formulation.Viscusi, ER., Sinatra, R., Onel, E., et al.[2022]
In a randomized controlled trial involving 57 patients undergoing midurethral sling placement, liposomal bupivacaine resulted in lower median pain scores on postoperative day 1 compared to a mixture of bupivacaine and lidocaine (20 mm vs 30 mm), indicating some efficacy in pain management.
Despite the initial lower pain scores, there were no significant differences in overall opioid and nonsteroidal anti-inflammatory drug consumption or in quality of recovery scores after 7 days, suggesting that liposomal bupivacaine may not provide a clinically significant advantage over traditional pain management methods.
Liposomal Bupivacaine Versus Bupivacaine Hydrochloride with Lidocaine during Midurethral Sling Placement: A Randomized Controlled Trial.Iwanoff, C., Salamon, C.[2020]

References

Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers. [2018]
The safety of liposome bupivacaine, a novel local analgesic formulation. [2022]
Liposomal Bupivacaine Versus Bupivacaine Hydrochloride with Lidocaine during Midurethral Sling Placement: A Randomized Controlled Trial. [2020]
The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. [2022]
Retrospective Assessment of the Use of Liposomal Bupivacaine in Lumbar Fusions in Immediate Postoperative Hospital Care. [2021]
Bupivacaine Versus Liposomal Bupivacaine for Postoperative Pain Control after Augmentation Mammaplasty: A Prospective, Randomized, Double-Blind Trial. [2022]
Bupivacaine liposomal versus bupivacaine: comparative review. [2021]
Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study. [2022]
Liposomal versus plain bupivacaine for pain control following vaginal reconstruction. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security